Etanercept

Study	Exclusion reasons	Rmk	Reference
Odorici, 2019	case report or case series	EXCLUDED: case-series (all patients treated with secukinumab, infliximab, etanercept or adalimumab).	Odorici J Eur Acad Dermatol Venereol 2019; 33:e374-e377 10.1111/jdv.15671
Salat, 2016	other reason	EXCLUDED: study on questions asked to therapeutic consultation service, without data on fetal/neonatal/maternal safety outcomes.	Salat Eur J Hosp Pharm 2016; 23:161-165 10.1136/ejhpharm-2015-000770
Accortt, 2015	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: the data included in this abstract of congress has been published more recently and extensively by Carman 2017.	Accortt N Annals of the rheumatic diseases 2015;74(2): 788.3-789
Chambers, 2007	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: more recent publication included these data: Carman 2017. Updates of these data regularly published (Chambers 2007; Accortt 2015)	Chambers C 2007;56(S2):AB10.
Accortt-psoriasis, 2015	repeat population groups, duplicate reports (most recent study included)	EXCLUDED: the data included in this abstract of congress has been published more recently and extensively by Carman 2017.
Diav-Citrin (Unexposed control), 2014	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses were performed for the group of 3 TNF-α inhibitors (ADA, ETA, and IFX), without individual analysis by substance and provided raw data did not allow to calculate the birth defects (ex: denominator not available for malformation rates).	Diav-Citrin O Reprod Toxicol 2014;43:78-84 10.1016/j.reprotox.2013.11.004
Diav-Citrin (Control exposed to other treatments), 2014	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses were performed for the group of 3 TNF-α inhibitors (ADA, ETA, and IFX), without individual analysis by substance and provided raw data did not allow to calculate the birth defects (ex: denominator not available for malformation rates).	Diav-Citrin O Reprod Toxicol 2014;43:78-84 10.1016/j.reprotox.2013.11.004
Bérard, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses performed for the group of pregnancies exposed antiTNFa and other immunosuppressants (adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, anakinra, rituximab and tocilizumab), without analysis for each substance.	Bérard A Ann Rheum Dis 2018;77:500-509 10.1136/annrheumdis-2017-212078
Verstappen, 2011	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: no specific analysis for substance. 4 groups according to anti-TNF exposure: (1) anti-TNF and MTX and/or LEF at conception (n=21); (2) anti-TNF at conception (n=50); (3) anti-TNF prior to conception (n=59); (4) no exposure to anti-TNF (n=10).	Verstappen SM Ann Rheum Dis 2011;70:823-6 10.1136/ard.2010.140822
Broms, 2016	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses performed for the group of pregnancies exposed to antiTNFa, without analysis for each substance: ETN (338), ADA (77), IFX (28), GOL (4) (data obtained through personal communication with authors by Mirdamadi et al., 2018).	Broms G Scand J Gastroenterol 2016;51:1462-1469 10.1080/00365521.2016.1208269
Palmsten, 2012	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of Disease-Modifying Antirheumatic Drug (DMARD) as a whole, without distinction between treatments.	Palmsten Arthritis Care Res (Hoboken) 2012; 64:1730-8 10.1002/acr.21807
Eudy, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of pregnancy outcomes in women with RA versus healthy controls, without distinction between treatments.	Eudy Clin. Rheumatol. 2018; 37:789-794 10.1007/s10067-017-3939-4
Mills, 2020	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: developmental milestone outcomes analysis before or after maternal AIRD diagnosis. No detailed analysis according to the medications.	Mills J. Rheumatol. 2020; 47:149-154 10.3899/jrheum.181067
Broms, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis performed according illness status without distinction between treatments.	Broms Acta Derm. Venereol. 2018; 98:728-734 10.2340/00015555-2923
Cooper, 2014	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Tumor necrosis factor inhibitors (TNFi) (etanercept, infliximab, and adalimumab) analyzed as a whole, without distinction between treatments.	Cooper 2014; 66:444-50 10.1002/art.38262
Tsao, 2019	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: biologic treatments (Infliximab, Etanercept, Adalimumab,abatacept, alefacept, certolizumab pegol,golimumab, rituximab, tocilizumab and ustekinumab) studied as a whole, without distinction between treatments.	Tsao BMJ Open 2019; 9:e023714 10.1136/bmjopen-2018-023714
Sugawara, 2019	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: outcomes of the pregnancies exposed to Etanercept were not reported separately.	Sugawara Lupus 2019; 28:1407-1416 10.1177/0961203319877258
Shimada, 2019	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Certolizumab pegol and etanercept analyzed as a whole.	Shimada Clin. Rheumatol. 2019; 38:1453-1458 10.1007/s10067-019-04450-3
Gaujoux-Viala, 2009	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: outcomes of pregnancies exposed to TNFi reported as a whole without distinction between treatments.	Gaujoux-Viala Clinical and Experimental Rheumatology 2009; 27:1059-.
Viktil, 2009	pattern of exposure	EXCLUDED: Pattern of exposure without data on fetal/maternal/neonatal safety outcomes.	Viktil KK Pharmacoepidemiol Drug Saf 2009;18:737-42 10.1002/pds.1775
Palmsten, 2017	pattern of exposure	EXCLUDED: Pattern of exposure without safety data on fetal/maternal/neonatal safety outcomes.	Palmsten Rheumatology (Oxford) 2017; 56:561-569 10.1093/rheumatology/kew448